Clinical Edge Journal Scan

Preoperative imaging of T1 tumors estimates postoperative pathology size in early invasive breast cancer


 

Key clinical point: Imaging can be dependably used for estimating the size of clinical T1 tumors to plan lumpectomy; however, overestimation by preoperative imaging size (PIS) should be considered for larger tumors.

Major finding: Significant correlation was observed between PIS and postoperative pathology size (PPS), highest when estimated with ultrasound (correlation coefficient [r] 0.628) followed by mammography (r 0.571; both P < .001). Although ultrasound underestimated T1 (mean difference between PIS and PPS [MD] 3.47 mm; 95% CI 4.02 to 2.91 mm) and T2 (MD 2.20 mm; 95% CI 3.39 to 1.02 mm) tumors, mammogram underestimated T1 tumors (MD 2.91; 95% CI 3.51 to 2.32) and overestimated T2 tumors (MD 0.90; 95% CI 0.44 to 2.24), all within the range of concordance.

Study details: This study identified 1512 tumors in 1502 patients with invasive breast cancer who underwent their first surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Kapur H et al. Accuracy of preoperative imaging estimates: Opportunities to de-escalate surgery for early invasive breast cancer. Am J Surg. 2022 (Mar 30). Doi: 10.1016/j.amjsurg.2022.03.053

Recommended Reading

1 in 7 breast cancer patients report worsening personal finances
MDedge Hematology and Oncology
Which breast cancer surgery leads to better quality of life?
MDedge Hematology and Oncology
Recurrent DCIS can be genetically distinct from primary lesion
MDedge Hematology and Oncology
Trastuzumab deruxtecan bests trastuzumab emtansine in HER2+ metastatic breast cancer
MDedge Hematology and Oncology
Ribociclib prolongs survival in HR+/HER2- advanced breast cancer
MDedge Hematology and Oncology
Neoadjuvant letrozole-palbociclib combo might allow sparing chemotherapy in high-risk ER+/HER2- early breast cancer
MDedge Hematology and Oncology
Abemaciclib+ET shows a manageable safety profile in HR+/HER2-, high-risk early breast cancer
MDedge Hematology and Oncology
Switching to lapatinib shows promise in HER2+ trastuzumab-refractory metastatic breast cancer
MDedge Hematology and Oncology
Breast cancer: Depression and hormone therapy significant risk factors for worse fatigue trajectory
MDedge Hematology and Oncology
Excellent prognosis in young patients with node-negative TNBC and high sTIL
MDedge Hematology and Oncology